🇺🇸 Gonadotropin in United States

801 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Ovarian Hyperstimulation Syndrome — 280 reports (34.96%)
  2. Off Label Use — 80 reports (9.99%)
  3. Drug Ineffective — 68 reports (8.49%)
  4. Ascites — 63 reports (7.87%)
  5. Abortion Spontaneous — 56 reports (6.99%)
  6. Headache — 55 reports (6.87%)
  7. Maternal Exposure During Pregnancy — 53 reports (6.62%)
  8. Nausea — 52 reports (6.49%)
  9. Drug Exposure During Pregnancy — 51 reports (6.37%)
  10. Ectopic Pregnancy — 43 reports (5.37%)

Source database →

Gonadotropin in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Other approved in United States

Frequently asked questions

Is Gonadotropin approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Gonadotropin in United States?

Uludag University is the originator. The local marketing authorisation holder may differ — check the official source linked above.